# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab,...
Cantor Fitzgerald analyst Josh Schimmer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight.
JMP Securities analyst Silvan Tuerkcan initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Market Outperform rati...
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $...
RBC Capital analyst Gregory Renza maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target ...
HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price...
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $...
HC Wainwright & Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Buy and maintains $65 price...
BTIG analyst Justin Zelin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Targ...